Cutrell A, Hernandez J, Brothers C et al. 2008 Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction.

Slides:



Advertisements
Similar presentations
Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)
C-REACTIVE PROTEIN, FIBRINOGEN, AND CARDIOVASCULAR DISEASE PREDICTION By Patrick Whitledge PA-S2 South University Physician Assistant Program.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
1FHI 360 Nigeria. 2USAID Nigeria
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
Cutrell A, Hernandez J, Brothers C et al Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
Introductory talk D Costagliola.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
17th Annual Canadian Conference on HIV/AIDS Research (CAHR 2008) Montreal, Quebec / April 24-27, th Annual Canadian Conference on HIV/AIDS Research.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
4S: Scandinavian Simvastatin Survival Study
Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
- Published online December 23, 2008 DOI: /S (08) Study sponsored and funded by Assistance Publique.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.
Assessment of cardiovascular risk in a 3-year- cohort of HIV-infected patients of Sub-Saharan origin living in France or Côte d’Ivoire and starting antiretroviral.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.
EPZICOM ® Virologic Response in ART-Naïve Patients with Baseline Viral Loads Above and Below 100,000c/mL Using the A5202 Endpoint K. Pappa, J. Hernandez,
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Title slide.
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice.
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
AIM HIGH Niacin plus Statin to prevent vascular events
HDL cholesterol and cardiovascular risk Epidemiological evidence
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
HDL cholesterol and cardiovascular risk
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
FATS- Familial Atherosclerosis Treatment Study
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
Neil J. Stone et al. JACC 2014;63:
A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids.
Switch to DTG-containing regimen
Baseline characteristics of HPS participants by prior diabetes
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Baseline Characteristics of the Subjects*
Switch to DTG-containing regimen
Study Flow Diagram Thompson A, et al. JAMA 2008;299:
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
DTG + 3TC vs DTG + TDF/FTC GEMINI.
Presentation transcript:

Cutrell A, Hernandez J, Brothers C et al Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction (MI)? No association identified in pooled summary of 54 clinical trials A Cutrell, J Hernandez, C Brothers, J Yeo, W Burkle, W Spreen. XVII International AIDS Conference, 3-8 August 2008, Mexico City

Cutrell A, Hernandez J, Brothers C et al Background and Objective The D:A:D study group recently reported an unexpected increase in risk of MI with ABC and ddI in a large, prospective observational cohort (Lancet 2008; 371: ). To determine whether there is an increase in cardiovascular events associated with ABC containing CART as compared to non-ABC containing CART using GSK-sponsored clinical trials contained in the GSK HIV Data Repository.

Cutrell A, Hernandez J, Brothers C et al Methods (1) GSK HIV Data Repository – history/purpose GSK-sponsored clinical trials with > 24 weeks of follow up with data from were analyzed. –Data from 54 clinical trials analyzed: 13/54 adult trials were randomized for ABC vs control 33/54 trials included ABC in background ART 8/54 trials did not include ABC Includes data from subjects (14174 adults and 509 children) Descriptive statistics were summarized for naïve and experienced subjects treated with and without ABC.

Cutrell A, Hernandez J, Brothers C et al Methods (2) To capture events of interest (myocardial ischemia or infarction) all data were queried for events coded as “ Coronary Artery Disorders ” and “ Ischemic Coronary Artery Disorders ” using MeDRA –Specific preferred terms included: coronary artery atherosclerosis, coronary artery disease, coronary artery occlusion, acute MI, angina pectoris, angina unstable, MI and myocardial ischemia.

Cutrell A, Hernandez J, Brothers C et al Methods (3) All fatal cases (any cause) in the HIV Data Repository were reviewed by an external cardiologist. Framingham risk not calculated at baseline – not all factors routinely collected –Smoking, hypertension, HDL levels Rates per 1000 person/years were calculated, and Poisson regression models were used to calculate unadjusted relative rates and 95% confidence intervals using SAS.

Cutrell A, Hernandez J, Brothers C et al Demographic and HIV-disease Characteristics at Baseline ADULT NAIVEADULT EXPERIENCED ABC N=5859 No ABC N=2406 ABC N=3643 No ABC N=2266 Age at Screening, n Median, year (min-max) (17-78) (18-74) (18-78) (18-74) Race, n White Black % 29% % 22% % 21% % 16% Sex, n Male % % % % Viral Load (log 10 ), n Median (Min-Max) ( ) ( ) ( ) ( ) CD4 Count, n Median (Min-Max) (0-1883) (0-1729) (0-2089) (0-1799)

Cutrell A, Hernandez J, Brothers C et al Baseline Lipids and Glucose (mmol/L) n Median (Min-Max) ADULT NAIVEADULT EXPERIENCED ABC N=5859 No ABC N=2406 ABC N=3643 No ABC N=2266 Cholesterol ( ) ( ) ( ) ( ) LDL ( ) ( ) ( ) ( ) HDL ( ) ( ) ( ) ( ) Triglycerides ( ) ( ) ( ) ( ) Glucose ( ) ( ) ( ) ( )

Cutrell A, Hernandez J, Brothers C et al CV Outcomes - Exposure to ABC Compared with No Exposure to ABC Exposure to ABC Events /Patients FrequencyEvents /Person- Years Rate /1000 Person- Years Relative rate (95% CI) Any Myocardial Infarction or Acute Myocardial Infarction: None 7/ %11/ ABC CART11/ %16/ (0.40,1.86) Any ischemic Coronary Artery Disease or Disorder: None 21/ %27/ ABC CART24/ %27/ (0.35,1.01)

Cutrell A, Hernandez J, Brothers C et al CV Outcomes - Exposure to ABC or No ABC (12 Adult Randomized Trials) Exposure to ABC Events /Patients FrequencyEvents /Person- Years Rate /1000 Person- Years Relative rate (95% CI) Any Myocardial Infarction or Acute Myocardial Infarction: None 6/ %7/ ABC CART2/ %4/ (0.15 – 1.79) Any ischemic Coronary Artery Disease or Disorder: None 13/ %13/ ABC CART5/ %8/ ( )

Cutrell A, Hernandez J, Brothers C et al Strengths and Limitations Prospective clinical trial data with large number of patients exposed to ABC, consistent data collection Standard and real-time monitoring and follow up of all reported AEs External expert review supportive Post-hoc analysis Duration of exposure on average weeks Studies not designed to detect CV risk specifically Low event rate therefore less power

Cutrell A, Hernandez J, Brothers C et al Conclusion Overall, among pts in the GSK HIV Data Repository: –the incidence rate of MI and Coronary Artery Disorders was low –there was no difference in incidence of ischemic coronary artery events or myocardial infarction in subjects who received abacavir-containing vs. non- ABC containing CART Further study is needed to fully evaluate the association of ABC and cardiovascular disease.

Cutrell A, Hernandez J, Brothers C et al What’s Next to Further Address the Question? Analysis of Internal Clinical Trial Data Continued vigilance of spontaneous event data and published literature  In all future studies, incorporate cardiovascular risk factor and biomarker collection  Mechanism research  Additional cohort collaborations  Analyze inflammatory markers in current and future studies

Cutrell A, Hernandez J, Brothers C et al HEAT Biomarker Analysis: Geometric Mean (95% CI) by Study Week (ITT-E) n (obs) Epzicom = Truvada = Interleukin 6 (IL-6) High Sensitivity C-Reactive Protein (hsCRP) Poster LBPE1138 Thursday August 7, 2008

Cutrell A, Hernandez J, Brothers C et al Acknowledgments The authors wish to thank… Harry Staines, Suki Pabla, Dupe Bassey, Lee Tombs and Pinal Patel at SRG Interesource Satellite Operations for statistical support Drs. Peter Kowey & Gary Koch for expert input Investigators who supported the clinical trials All of the patient volunteers.